Compound advances into larger clinical trials; could pave the way for other future medicines as well
In 2012, autism dominated headlines as never before. Public awareness skyrocketed with new updates on autism’s estimated prevalence (1 in 88) and costs to society ($137 billion per year nationally). Controversy roiled around proposed changes to how autism spectrum disorder (ASD) will be diagnosed in the years ahead.
New York, N.Y. (December 3, 2012) – Autism Speaks and Delivering Scientific Innovation for Autism, LLC (DELSIA), its non-profit affiliate, announced today a partnership between DELSIA and Seaside Therapeutics (Cambridge, Mass.) that aims to discover biomarkers that can be used to facilitate the development of safe, effective and personalized treatments of autism spectrum disorders (ASD).